Complete News World

Medicamento aprovado pela Anvisa para tratamento do HIV

A drug approved by Anvisa for the treatment of HIV

The National Health Surveillance Agency (Anvisa) announced Monday (29) that it has approved a new drug to treat HIV. It is a combination of two substances, lamivudine and dolutegravir sodium, in one tablet. “Advances in the treatment of people infected with the virus that causes AIDS, because it combines in a daily dose two antiretroviral drugs that were not available in one pill. The possibility of single doses simplifies treatment and patient compliance.” .

HIV drugs / photo reproduçã:

According to the agency contained in the leaflet of the approved package, the new drug reduces the amount of HIV in the patient’s body, keeping it at a level considered low. In addition to the drug that increases the number of CD4 cells that play an important role in a healthy immune system, helping to fight infections.

The drug may be prescribed for the purpose of the complete treatment of HIV infection in adults and adolescents over 12 years of age who weigh at least 40 kg, provided that they do not have a history of previous antiretroviral therapy or to replace the current antiretroviral regimen in persons with HIV. suppression.

The first phase of human trials, Phase 1, has been officially published in the US National Institutes of Health (NIH) registry. The initial studies will include 56 people between the ages of 18 and 50 who do not have the virus.

In Brazil, antiretrovirals have been distributed free of charge since 1996 by the Unified Health System (SUS), which guarantees treatment of people living with HIV, regardless of their viral load.

See also  Science and Technology in Covid-19 Vaccines - MonitoR7

The registration was granted to the British pharmaceutical company GlaxoSmithKline Brasil Ltda which, according to Anvisa, provided after efficacy and safety studies with data supporting the authorized indications.

(Featured image: Anvisa agrees to beg for an HIV treatment in one pill: Fonte/